Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy

被引:128
作者
Schena, FP [1 ]
机构
[1] Univ Bari, Policlin, Div Nephrol Dialysis & Transplantat, Dept Emergency & Organ Transplantat, I-70124 Bari, Italy
关键词
renal registries; incidence; prevalence; outcome measures;
D O I
10.1046/j.1523-1755.2000.07407.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Renal replacement therapy (RRT) remains the most important tool for all patients with end-stage renal disease (ESRD) in the world. Patients are usually listed in the national renal registries which report demographic data, incidence, prevalence and outcome. Differences in acceptance of the RRT, patient demographics, socioeconomic burdens and national health care legislature influence the validity of international comparisons of ESRD therapy. For this reason, the renal registries decided to organize an international collaborative study group, the International Federation of Renal Registries (IFRR), for improving the standardization of renal databases and for promoting international collaborative studies. Demographic data from renal registries in 1996 showed that approximately 1,000,000 of ESRD patients received RRT throughout the world and approximately 200,000 new patients started RRT. The different distribution of patients in the world is strongly influenced by the level of gross domestic product (GDP), since economical crisis may influence the number of patients starting RRT. The reported incidence and prevalence values of ESRD patients in RRT from the renal registries show these differences. The mortality rate of these patients is notably influenced by the percentage of enrolled diabetic RRT patients. Therefore, important differences in outcome of RRT depend on the underlying disease which is a determinant factor of prognosis. Other factors responsible for the outcome are represented by dialysis dose, type of membrane, erythropoietin and nutritional status.
引用
收藏
页码:S39 / S45
页数:7
相关论文
共 24 条
[1]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[2]   From outcomes research to disease management: A guide for the perplexed [J].
Epstein, RS ;
Sherwood, LM .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (09) :832-837
[3]  
Foley RN, 1998, J AM SOC NEPHROL, V9, P267
[4]   Cardiac disease in the diabetic dialysis patient [J].
Foley, RN ;
Parfrey, PS .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (05) :1112-1113
[5]   The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (01) :53-61
[6]   Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
KIDNEY INTERNATIONAL, 1996, 49 (05) :1379-1385
[7]   Effect of the dialysis membrane on mortality of chronic hemodialysis patients [J].
Hakim, RM ;
Held, PJ ;
Stannard, DC ;
Wolfe, RA ;
Port, FK ;
Daugirdas, JT ;
Agodoa, L .
KIDNEY INTERNATIONAL, 1996, 50 (02) :566-570
[8]  
HELD PJ, 1994, DEATH DIALYSIS, P12
[9]  
IGLEHART JK, 1993, NEW ENGL J MED, V328, P328
[10]  
KJELLSTRAND CM, 1994, DEV NEPHROL, V35, P55